Tempest Therapeutics, Inc. — Director's Dealing 2012

Dec 7, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2012-12-05

Reporting Person: BLECK CHRISTOPHER A (VP and COO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-12-05	Stock Option	$7.80	A	52000	Acquired	2022-12-04	Common Stock (52000)	Direct

Footnotes

F1: The stock option will become exercisable as to 25% of the original number of shares (the "Shares") on the first anniversary of the Vesting Commencement Date and to an additional 6.25% of the Shares at the end of each successive three-month period following the Vesting Commencement Date until the fourth anniversary of the Vesting Commencement Date. For purposes of this stock option grant, "Vesting Commencement Date" shall mean December 31, 2012.